Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Marpai Q2 EPS $(0.34), Sales $5.56M Miss $6.22M Estimate

Marpai (NASDAQ:MRAI) reported quarterly losses of $(0.34) per share. The company reported quarterly sales of $5.56 million which missed the analyst consensus estimate of $6.22 million by 10.66 percent.
byMichael Horton
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Marpai (NASDAQ:MRAI) reported quarterly losses of $(0.34) per share. The company reported quarterly sales of $5.56 million which missed the analyst consensus estimate of $6.22 million by 10.66 percent.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

By Happy Mohamed
December 16, 7:37 PM
Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY